The FDA approves the first medication for treating hot flashes.
Women who are suffering from the uncomfortable hot flashes associated with menopause may find relief with a new drug. The FDA authorized fezolinetant (Veozah) in May 2023. It's the first medication made expressly to lessen the frequency and intensity of hot flashes and sweats that accompany a woman's declining estrogen levels. Fezolintant is a non hormonal medication that modifies the brain's regulation of body temperature, in contrast to hormone replacement therapy, which is the primary treatment for hot flashes and may increase the risk of blood clots or breast cancer. The medication needs to be taken consistently, and it needs to be taken with regular blood tests to monitor for any potential side effects, such as liver damage. Back discomfort, diarrhea, sleeplessness, and abdominal pain are possible additional side effects. Aside from hormone-based pharmaceuticals, other non hormonal treatments for hot flashes include antidepressants, blood pressure treatments, and medications for nerve pain.
Depositphotos
